This video was not produced by NetworkPharma.tv but has been included within the library because it is directly relevant to individuals who work in medcomms and is here with permission from its owner.

= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =

For this edition of their webinar series “Keeping it real”, Vitaccess’ Founder and CEO Dr Mark Larkin and Senior Consultant Sam Llewellyn talked about real-world evidence in rare disease. Vitaccess is an established partner in real-world evidence in the field of rare diseases, with several studies conducted globally. We used our international CMT&Me study, which measures the impact of Charcot-Marie-Tooth diseases on patients’ daily lives, as a case study. Sponsored by Pharnext, and co-created with patient advocacy groups from each country in which the study is being conducted, the CMT&Me study has unveiled the patients’ reality of living with CMT. Joining us to share what the study has meant for them were Pharnext’s Chief Commercial Officer Xavier Paoli and Italian patient advocacy group ACMT-Rete’s Head of Scientific and Foreign Relations Filippo Genovese.

Recorded as a live webinar, 10 June 2021, by Vitaccess and is included here with their permission.

Mark’s LinkedIn page is at https://www.linkedin.com/in/marklarkin-vitaccess/

Sam’s LinkedIn page is at https://www.linkedin.com/in/samuelllewellyn/

Xavier’s LinkedIn page is at https://www.linkedin.com/in/xavier-paoli-2638831/

Filippo’s LinkedIn page is at https://www.linkedin.com/in/filippogenovese/

You can find out more about Vitaccess at https://vitaccess.com

= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =

We are building a library of free webcasts and other video content for the global MedComms Community and others at http://www.networkpharma.tv and we’d welcome your suggestions for new content.